Page 23 - BH-1-2

Brain & Heart Pemafibrate in patients with dyslipidemia

The non-HDL levels significantly decreased following was no significant difference in the percent change of TG
treatment with pemafibrate 0.2 mg/day compared to between patients treated with pemafibrate at 0.2 mg/day
placebo (MD: −7.70; 95% CI: −10.66 – −4.74; P < 0.00001; compared to those treated with fenofibrate at 200 mg/day
I² = 33%) (Figure 12). Pemafibrate at 0.2 mg/day also (Figure 15) (MD: −2.90; 95% CI: −12.90 – 7.11; P = 0.57;
demonstrated a greater decrease in TC (MD: −2.58; 95% I² = 83%).
CI: −4.96 – −0.20]; P = 0.03; I² = 38%) (Figure 13) and TG When comparing 0.1 mg/day of pemafibrate with
levels (MD: −47.30; 95% CI: −53.99 – −40.60; P = 0.00001; placebo, HDL levels significantly increased with
I² = 47%) (Figure 14) compared to placebo. However, LDL pemafibrate therapy (MD: 13.82; 95% CI: 6.70 – 20.95;
levels were lower in the placebo group (MD: 11.42; 95% P = 0.0001; I² = 81%) (Figure 16). TG levels (MD: −43.72;
CI: 5.52 – 17.32; P = 0.0001; I² = 60%). In addition, there 95% CI: −53.51 – −33.93; P < 0.00001; I² = 60%) (Figure 17),

Figure 9. Significantly higher high-density lipoprotein levels following treatment with pemafibrate at 0.4 mg/day.

Figure 10. No difference in the incidence of adverse events between groups.

Figure 11. No difference in total cholesterol levels between the groups.

Figure 12. Significantly lower non-high-density lipoprotein levels following treatment with pemafibrate at 0.2 mg/day.

Volume 1 Issue 2 (2023) 7 https://doi.org/10.36922/bh.1629